Alberto Paladini

Alberto Paladini

Auto-generated profile, based on publicly available information

Alberto Paladini

Postgraduate School in Internal Medicine, Dipartimento di Medicina Interna, Ospedali Riuniti di Ancona and Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2021 in Scandinavian Journal of Immunology
Verified
Journal Article
Open access
PDF file
MDMaria Giovanna Danieli
Maria Giovanna Danieli
MPMario Andrea Piga
Mario Andrea Piga
APAlberto Paladini
Alberto Paladini
ELEleonora Longhi
Eleonora Longhi
CMCristina Mezzanotte
Cristina Mezzanotte
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
The coronavirus disease‐19 (COVID‐19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) challenged globally with its morbidity and mortality. A small percentage of affected patients (20%) progress into the second stage of the disease clinically presenting with severe or fatal involvement of lung, heart and vascular system, all contributing to multiple‐organ failure. The so‐called ‘cytokines storm’ is considered the pathogenic basis of severe disease and it is a target for treatment with corticosteroids, immunotherapies and intravenous immunoglobulin (IVIg). We provide an overview of the role of IVIg in the therapy of adult patients with COVID‐19 disease. After discussing the possible underlying mechanisms of IVIg immunomodulation in COVID‐19 disease, we review the studies in which IVIg was employed. Considering the latest evidence that show a link between new coronavirus and autoimmunity, we also discuss the use of IVIg in COVID‐19 and anti‐SARS‐CoV‐2 vaccination related autoimmune diseases and the post‐COVID‐19 syndrome. The benefit of high‐dose IVIg is evident in almost all studies with a rapid response, a reduction in mortality and improved pulmonary function in critically ill COVID‐19 patients. It seems that an early administration of IVIg is crucial for a successful outcome. Studies’ limitations are represented by the small number of patients, the lack of control groups in some and the heterogeneity of included patients. IVIg treatment can reduce the stay in ICU and the demand for mechanical ventilation, thus contributing to attenuate the burden of the disease.

8 February 2023
Verified
Book Chapter
Closed access
YAYekbun Adiguzel
Yekbun Adiguzel
LALaura Andreoli
Laura Andreoli
EAEleonora Antonelli
Eleonora Antonelli
LALambros Athanassiou
Lambros Athanassiou
PAPanagiotis Athanassiou
Panagiotis Athanassiou
DZDaniela Noa Zohar
Daniela Noa Zohar


11 August 2022
Verified
Book Chapter
Closed access
PDF file
MDMaria Giovanna Danieli
Maria Giovanna Danieli
APAlberto Paladini
Alberto Paladini
LPLuca Passantino
Luca Passantino
ELEleonora Longhi
Eleonora Longhi